Research programme: respiratory hypersensitivity immunotherapies - DBV Technologies/Stallergenes Greer plc

Drug Profile

Research programme: respiratory hypersensitivity immunotherapies - DBV Technologies/Stallergenes Greer plc

Alternative Names: Birch pollen allergen immunotherapy - DBV Technologies/Stallergenes Greer plc

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator DBV Technologies; Stallergenes SA
  • Developer DBV Technologies; Stallergenes Greer plc
  • Class Allergens; Allergy immunotherapies; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Tree pollen hypersensitivity
  • No development reported Respiratory tract disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Respiratory-tract-disorders in France (Intradermal, Patch)
  • 18 Oct 2013 DBV Technologies and Stallergenes SA agree to co-develop Birch pollen hypersensitivity immunotherapy in France
  • 18 Oct 2013 Preclinical trials in Tree pollen hypersensitivity in France (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top